GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (BSP:N1BI34) » Definitions » Cyclically Adjusted PS Ratio

Neurocrine Biosciences (BSP:N1BI34) Cyclically Adjusted PS Ratio : 12.74 (As of Jun. 05, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Neurocrine Biosciences Cyclically Adjusted PS Ratio?

As of today (2024-06-05), Neurocrine Biosciences's current share price is R$36.19. Neurocrine Biosciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was R$2.84. Neurocrine Biosciences's Cyclically Adjusted PS Ratio for today is 12.74.

The historical rank and industry rank for Neurocrine Biosciences's Cyclically Adjusted PS Ratio or its related term are showing as below:

BSP:N1BI34' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 7.31   Med: 24.53   Max: 125.15
Current: 11.7

During the past years, Neurocrine Biosciences's highest Cyclically Adjusted PS Ratio was 125.15. The lowest was 7.31. And the median was 24.53.

BSP:N1BI34's Cyclically Adjusted PS Ratio is ranked worse than
94.89% of 744 companies
in the Drug Manufacturers industry
Industry Median: 2.05 vs BSP:N1BI34: 11.70

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Neurocrine Biosciences's adjusted revenue per share data for the three months ended in Mar. 2024 was R$1.238. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is R$2.84 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Neurocrine Biosciences Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Neurocrine Biosciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Cyclically Adjusted PS Ratio Chart

Neurocrine Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.50 23.79 14.91 14.85 12.07

Neurocrine Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.53 9.93 10.97 12.07 12.09

Competitive Comparison of Neurocrine Biosciences's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurocrine Biosciences's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Neurocrine Biosciences's Cyclically Adjusted PS Ratio falls into.



Neurocrine Biosciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Neurocrine Biosciences's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=36.19/2.84
=12.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurocrine Biosciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Neurocrine Biosciences's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.238/131.7762*131.7762
=1.238

Current CPI (Mar. 2024) = 131.7762.

Neurocrine Biosciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.039 99.621 0.052
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.032 100.470 0.042
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 0.000 102.862 0.000
201706 0.012 103.349 0.015
201709 0.108 104.136 0.137
201712 0.176 104.011 0.223
201803 0.130 105.290 0.163
201806 0.203 106.317 0.252
201809 0.322 106.507 0.398
201812 0.266 105.998 0.331
201903 0.292 107.251 0.359
201906 0.373 108.070 0.455
201909 0.476 108.329 0.579
201912 0.515 108.420 0.626
202003 0.597 108.902 0.722
202006 0.799 108.767 0.968
202009 0.748 109.815 0.898
202012 0.656 109.897 0.787
202103 0.679 111.754 0.801
202106 0.743 114.631 0.854
202109 0.800 115.734 0.911
202112 0.901 117.630 1.009
202203 0.792 121.301 0.860
202206 0.998 125.017 1.052
202209 1.027 125.227 1.081
202212 1.073 125.222 1.129
202303 1.128 127.348 1.167
202306 1.096 128.729 1.122
202309 1.218 129.860 1.236
202312 1.235 129.419 1.257
202403 1.238 131.776 1.238

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Neurocrine Biosciences  (BSP:N1BI34) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Neurocrine Biosciences Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurocrine Biosciences (BSP:N1BI34) Business Description

Traded in Other Exchanges
Address
12780 El Camino Real, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Neurocrine Biosciences (BSP:N1BI34) Headlines

No Headlines